Paget's Disease of Bone
Also known as: Osteitis deformans
Methodology & AI Transparency ⓘ
Paget's Disease of Bone Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is Paget's disease of bone? Paget's disease of bone is a chronic bone disorder.
- 2 Real-world patient consensus: Diagnostic registry M88.9: Paget's Disease of Bone is managed within Bone Density (aka Osteitis deformans).
- 3 Typical cash cost range: Primary evaluation for Paget's Disease of Bone incorporates dual-energy X-ray absorptiometry in Paget's Disease of Bone (M88.9: (DEXA) with FRAX) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Paget's Disease of Bone: maintaining 25-Hydroxy Vitamin D [Paget's Disease of Bone M88.9] within 40 – 65 ng/mL (M88.9).
Ask our AI Specialists anything about Paget's Disease of Bone
What Is Paget's Disease of Bone?
What is Paget's disease of bone? Paget's disease of bone is a chronic bone disorder. Normally, there is a process in which your bones break down and then regrow. In Paget's disease, this process is abnormal. There is excessive breakdown and regrowth of bone. Because the bones regrow too quickly, they are bigger and softer than normal. They may be misshapen and easily fractured (broken). Paget's usually affects just one or a few bones. What causes Paget's disease of bone? Researchers do not know for sure what causes Paget's disease. Environmental factors may play a role. In some cases, the disease runs in families, and several genes have been linked to the disease.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Paget's Disease of Bone (code M88.9) is trabecular microarchitectural thinning [Paget's Disease of Bone M88.9], Cross-referenced with NIH MeSH (Osteitis Deformans), which Osteoporosis, Vitamin D & Bone Density clinicians address while surveilling 25-Hydroxy Vitamin D [Paget's Disease of Bone M88.9] (40 – 65 ng/mL (M88.9)).
Common Symptoms & Clinical Signs
- • Pain , which may be due to the disease or to arthritis, which can be a complication of Paget's
- • Headaches and hearing loss , which can happen when Paget's disease affects the skull
- • Presentation of Paget's Disease of Bone (M88.9): fragility fracture of in Paget's Disease of Bone (M88.9: wrist, hip, or)
- • Secondary Paget's Disease of Bone clinical sign: gradual loss of in Paget's Disease of Bone (M88.9: standing height)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Paget's Disease of Bone Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M88.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoporosis, Vitamin D & Bone Density | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D [Paget's Disease of Bone M88.9] | 40 – 65 ng/mL (M88.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Calcium, Phosphorus in Paget's Disease of Bone (M88.9: & PTH) | Ca 8.9–10.1 mg/dL; PTH 15–65 pg/mL (M88.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CTX / P1NP in Paget's Disease of Bone (M88.9: Bone Turnover Markers) | Balanced remodeling on therapy (M88.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Paget's Disease of Bone
Treatment selection for Paget's Disease of Bone depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Paget's Disease of Bone)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Population how the body absorbs the medicine/how the medicine works in the body: What a 420-Participant Study Found A population PK/PD model was developed in Chinese healthy male subjects and postmenopausal osteoporotic women. British journal of clinical pharmacology • 2026-02-15 • Phase III Randomized Trial | N = 420 | 87/100 | PMID 40974130 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Filgotinib on the how the body absorbs the medicine of Atorvastatin, Rosuvastatin exposure was moderately higher with filgotinib getting both at the same time-GLSM ratios (90% CI), 1.68 (1.43-1.97) for C max ; 1.42 (1.30-1.57) for AUC inf -but this was not considered clinically relevant. Clinical pharmacology in drug development • 2022-02-15 • Randomized Controlled Trial | N = 27 | 82/100 | PMID 34468080 ↗ |
Paget's Disease of Bone Patient Community & “People Like Me” Threads
Filter Paget's Disease of Bone community threads and patient logs by age, biological sex, dosage, and treatment duration.